Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
BTIG Reiterates Buy Rating on Adicet Bio Inc. (ACET)
August 14, 2024 6:11 AM EDTBTIG analyst Justin Zelin reiterated a Buy rating and $6.00 price target on Adicet Bio Inc. (NASDAQ: ACET).
The analyst comments "Adicet reported 2Q24 earnings, with expansion of ADI-001 autoimmune clinical development beyond lupus nephritis to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil... More



